

71

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): **BIGGADIKE, et. al.**

16/10

Docket No.

PG4735

Serial No.
10/067,010

Filing Date
02/04/2002

Examiner
BADIO

Group Art Unit
1616

Invention:

NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVE COMPOSITIONS



RECEIVED
NOV 12 2003
TECHNICAL 1600/2800

I hereby certify that this Supplemental IDS, PTO-1449 with References on CD
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

on

10/29/03
(Date)

Ban Younan

(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: Application of: **BIGGADIKE, et. al.**Serial No.: **10/067,010**Group Art Unit: **1616**Filed: **02/04/2002**Examiner: **BADIO**For: **NOVEL ANTI-INFLAMMATORY ANDROSTANE
DERIVATIVE COMPOSITIONS**

RECEIVED
NOV 12 2003
TECH CENTER 1600/2900

Director of the United States Patent and Trademark Office
 Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed on CD

☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the

issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☒ A duplicate copy of this paper is attached.

Respectfully Submitted,

 28 OCT 03

Attorney of Record: **James P. Riek**
Registration No.: **39,009**
Telephone: **(919) 483-8022**

CUSTOMER NO.: 23347

issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☒ A duplicate copy of this paper is attached.

Respectfully Submitted,



Attorney of Record: **James P. Riek**
Registration No.: **39,009**
Telephone: **(919) 483-8022**

28 OCT 03

CUSTOMER NO.: 23347

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.:
 PG4735

SERIAL NO:
 10/067,010

APPLICANT: BIGGADIKE, et. al.

FILING DATE:
 02/04/2002

GROUP
 1616

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	3,067,197	12/04/62	Agnello et al.			
	A2	3,639,434	02/01/72	Oxley et al.			
	A3	3,828,080	08/06/74	May et al.			
	A4	3,856,828	12/24/74	Phillips et al.			
	A5	3,981,894	09/21/76	Phillips et al.			
	A6	3,989,686	11/02/76	Phillips et al.			
	A7	4,093,721	06/06/78	Phillips et al.			
	A8	4,187,301	02/05/80	Edwards			
	A9	4,188,385	02/12/80	Edwards			
	A10	4,198,403	04/15/80	Alvarez			
	A11	4,261,984	04/14/81	Alvarez			
	A12	4,263,289	04/21/81	Edwards			
	A13	4,267,173	05/12/81	Draper			
	A14	4,285,937	08/25/81	Kalvoda			
	A15	4,310,466	01/12/82	Edwards			
	A16	4,377,575	03/22/83	Phillips et al.			
	A17	4,607,028	08/19/86	Schmidlin			
	A18	4,710,495	12/01/87	Bodor			
	A19	4,861,765	08/29/89	Jouveinal			
	A20	4,992,474	02/12/91	Skidmore et al.			
	A21	4,994,439	02/19/91	Longnecker et al.			
	A22	4,996,335	02/26/91	Bodor			
	A23	5,250,293	10/24/86	Gleich			
	A24	5,420,120	05/30/95	Boltralik			
	A25	5,707,984	01/13/98	Tjoeng et al.			
	A26	5,849,265	12/98	Li-Bovet et al.			
	A27	5,919,776	11/13/02	Hagmann et al.			
	A28	5,972,920	10/26/99	Seidel			
	A29	5,981,517	11/09/99	Bodor			
	A30	6,395,300	05/02	Straub, et al.			

Continued on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continued on page

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.:
 PG4735

SERIAL NO.:
 10/067,011

APPLICANT: BIGGADIKE, et. al.

FILING DATE:
 02/04/2002

GROUP
 1616

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	B1	92/14472	09/03/92	PCT			
	B2	94/21229	09/29/94	PCT			
	B3	95/31964	11/30/95	PCT			
	B4	96/19199	06/27/96	PCT			
	B5	97/05136	02/13/97	PCT			
	B6	97/15298	05/01/97	PCT			
	B7	97/24365	07/10/97	PCT			
	B8	97/46243	12/11/97	PCT			
	B9	98/34596	08/13/98	PCT			
	B10	98/43630	10/08/98	PCT			
	B11	99/01467	01/14/99	PCT			
	B12	99/25359	05/27/99	PCT			
	B13	99/32089	07/99	PCT			
	B14	00/38811	07/06/00	PCT			
	B15	00/57401	08/15/00	PCT			
	B16	01/04118	01/18/01	PCT			
	B17	01/15744	03/08/01	PCT			
	B18	01/20331	03/22/01	PCT			
	B19	01/62722	08/30/01	PCT			
	B20	01/78736	10/25/01	PCT			
	B21	01/78739	10/25/01	PCT			
	B22	01/78741	10/25/01	PCT			
	B23	01/78745	10/25/01	PCT			
	B24	02/00199	01/03/02	PCT			
	B25	02/007767	01/31/02	PCT			
	B26	02/008243	01/31/02	PCT			
	B27	02/012266	02/14/02	PCT			
	B28	02/013868	02/21/02	PCT			
	B29	02/26723	04/04/02	PCT			
	B30	02/053186	07/11/02	PCT			
	B31	02/066422	08/29/02	PCT			
	B32	02/070490	09/12/02	PCT			
	B33	02/076933	10/03/02	PCT			



Continued on page 3

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continued on page

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.:
 PG4735

SERIAL NO:
 10/067,010

APPLICANT: BIGGADIKE, et. al.

FILING DATE:
 02/04/2002

GROUP
 1616

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	B33	02/085296	10/31/02	PCT		
	B34	02/088167	11/07/02	PCT		
	B35	02/100879	12/19/02	PCT		
	B36	03/013427	02/20/03	PCT		
	B37	03/033000	04/24/03	PCT		
	B38	03/035668	05/01/03	PCT		
	B39	03/040691	05/15/03	PCT		
	B40	03/042229	05/22/03	PCT		
	B41	03/042230	05/22/03	PCT		
	B42	0004773	10/17/79	EP		
	B43	0057401	08/11/82	EP		
	B44	0135476	03/27/85	EP		YES US4607028
	B45	0179583	04/30/86	EP		
	B46	0416951	03/13/91	EP		
	B47	0418716	03/27/91	EP		YES WO9104252
	B48	0521455	01/07/93	EP		
	B49	0640616	03/01/95	EP		YES US5608093 ABSTRACT
	B50	0646593	04/05/95	EP		
	B51	2336693	02/06/75	DE		NO
	B52	2538569	03/03/77	DE		NO
	B53	1384372	02/19/75	GB		
	B54	1438940	06/09/76	GB		
	B55	1517278	07/12/78	GB		
	B56	2079755	01/27/82	GB		
	B57	2140800	12/05/84	GB		
	B58	04208267	07/29/92	JP		ABSTRACT
	B59	580494	10/24/86	FR		YES US4948583
	B60	109656	02/22/98	IL		
	B61	872389	04/02/87	ZA		

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continued on page

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.:
 PG4735

SERIAL NO:
 10/067,010

APPLICANT: BIGGADIKE, et. al.

FILING DATE:
 02/04/2002

GROUP
 1616

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

C1	Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535
C2	Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9&10), 1985, pp. 1781-1796.
C3	R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155
C4	Denis J. Kertesz et al., "Thiol Esters from Steroid 17 β -Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α -Acyates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328.
C5	Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 - 843
C6	John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708
C7	John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665
C8	Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145.
C9	S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736
C10	Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl- ¹⁸ F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584
C11	Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705
C12	Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517
C13	N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54
C14	R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209

Continued on page 5

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	


 RECEIVED
 NOV 12 2003
 TECH CENTER 1600/2003

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.:
 PG4735

SERIAL NO:
 10/067,010

APPLICANT: BIGGADIKE, et. al.

FILING DATE:
 02/04/2002

GROUP
 1616

 RECEIVED
 NOV 12 2003
 TECH CENTER 1604/2003

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

C15	Harold S. Nelson et al. "Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast," J. Allergy Clin. Immunol., Vol. 106, No. 6, December 2000, pp. 1088-1095
C16	Gunnar Johansson et al., "Comparison of Salmeterol/Fluticasone Propionate Combination With Budesonide in Patients With Mild-to-Moderate Asthma" Clin. Drug Invest. Vol. 21, No. 9, 2001, pp. 633-642.
C17	Bertil Pettersson et al., Re-evaluation of the classical Mycoplasma lipophilum cluster (Weisburg et al. 1989) and description of two new clusters in the hominis group based on 16S rDNA sequences," Int'l Journal of Systematic & Evolutionary Microbiology (2001) Vol. 51, pp. 633-643
C18	Sarah A. Lewis et al., "Association of specific allergen sensitization with socioeconomic factors and allergic disease in a population of Boston women", J. Allergy Clin. Immunol., Vol. 107, No. 4, April 2001, pp. 615-622
C19	Katherine A. Lyseng-Williamson et al., "Inhaled Salmeterol/Fluticasone Propionate Combination in Chronic Obstructive Pulmonary Disease," Am. J. Respir. Med. Vol. 1, No. 4, 2002, pp. 273-282
C20	Jeffrey W. Millard et al., "Solubilization by cosolvents Establishing useful constants for the log-linear model," Int'l Journal of Pharmaceutics Vol. 245, 2002, pp. 153-166
C21	C. Baumgarten et al., "Initial Treatment of Symptomatic Mild to Moderate Bronchial Asthma with the Salmeterol/Fluticasone Propionate (50/250µg) Combination Product (SAS 40023)" European Journal of Medical Research 2002, Vol. 7, pp. 1-7
C22	Stephen J. Fowler et al., "Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone" J. Allergy Clin. Immunol., Vol. 109, No. 6, June 2002, pp. 929-935
C23	Elizabeth F. Juniper et al., "Impact of Inhaled Salmeterol/Fluticasone Propionate Combination Product versus Budesonide on the Health-Related Quality of Life of Patients with Asthma," Am. J. Respir. Med., Vol. 1, No. 6, 2002, pp. 435-440
C24	William Busse et al., "Steroid-sparing effects of fluticasone propionate 100 µg and salmeterol 50 µg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 µg administered twice daily" J. Allergy Clin. Immunol., Vol. 111, No. 1, January 2003, pp. 57-65
C25	UENO H ET AL, "SYNTHESIS AND EVALUATION OF ANTIINFLAMMATORY ACTIVITIES OF A SERIES OF CORTICOSTEROID 17. ALPHA -ESTERS CONTAINING A FUNCTIONAL GROUP", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, Vol. 34, No. 8, August 1991, pp. 2468-2473
C26	PETER J BARNES, "Novel approaches and targets for treatment of Chronic Obstructive Pulmonary Disease" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 160, 1999, pp. S72-S79
C27	B.J O CONNER, "Combination Therapy", PULMONARY PHARMACOLOGY AND THERAPEUTICS, Vol.11, No. 5/6, 1998, pp. 397 - 399
C28	PETER J BARNES, "Chronic Obstructive Pulmonary Disease: new opportunities for drug development" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, Vol. 19, No.10, 1998, pp. 415 - 423

Continued on page 6

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.:
 PG4735

SERIAL NO.:
 10/067,010

APPLICANT: BIGGADIKE, et. al.

FILING DATE:
 02/04/2002

GROUP
 1616

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continued on page

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continued on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

C29	SIMON BOWLER, "Long acting beta agonists", AUSTRALIAN FAMILY PHYSICIAN, Vol 27, No. 12, 1998, pp. 1114-1118
C30	NAEDLE-RISHA R ET AL, "Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long acting beta-agonists with inhaled corticosteroids", THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, Vol 101, No. 9, September 2001, pp.2001-09
C31	T VAN DER MOLEN ET AL, "EFFECTS OF THE LONG ACTING BETA AGONIST FORMOTEROL ON ASTHMA CONTROL IN ASTHMATIC PATIENTS USING INHALED CORTICOSTEROIDS", Vol. 52, No. 6, 1997, pp. 535-539
C32	B.N. LUTSKY et al, "A Novel Class of potent Topical Anti-inflammatory Agents: 17 Benzoyleated, 7 - Halogeno Substituted Corticosteroids", Arzeneimittel Forschung, Vol. 29, No. 11, Nov. 1979, pp. 1662-1667
C33	PETER J. BARNES, "Efficacy of Inhaled Corticosteroids in Asthma", The Journal of Allergy and Clinical Immunology, Vol. 102, No. 4, pp. 531-538
C34	US Publication No. 2002/0081266 publ. on 06/27/02
C35	US Publication No. 2002/0103392 publ. on 08/01/02
C36	US Publication No. 2002/0165211 publ. on 11/07/02
C37	US Publication No. 2002/0173496 publ. on 11/21/02
C38	US Publication No. 2002/0177581 publ. on 11/28/02
C39	US Publication No. 2003/0073676 publ. on 04/17/03
C40	US Publication No. 2003/0109511 publ. on 06/12/03
C41	US Publication No. 2003/0144257 publ. on 07/31/03
C42	US Publication No. 2003/0158163 publ. on 08/21/03

Continued on page

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.